Alzheimer’s disease (AD) is characterized by the spread of tau pathology throughout the
cerebral cortex. This spreading pattern was thought to be fairly consistent across individuals, …

Context The ability to identify and quantify brain β-amyloid could increase the accuracy of a
clinical diagnosis of Alzheimer disease. Objective To determine if florbetapir F 18 positron …

Background Results of previous studies have shown associations between PET imaging of
amyloid plaques and amyloid-β pathology measured at autopsy. However, these studies …

Although amyloid imaging with PiB-PET ([C-11]Pittsburgh Compound-B positron emission
tomography), and now with F-18-labeled tracers, has produced remarkably consistent …

An 18 F-labeled PET amyloid-β (Aβ) imaging agent could facilitate the clinical evaluation of
late-life cognitive impairment by providing an objective measure for Alzheimer disease (AD) …

Introduction EXPEDITION and EXPEDITION2 were identically designed placebo-controlled
phase 3 studies assessing effects of solanezumab, an antiamyloid monoclonal antibody …

Plasma phospho-tau (p-tau) species have emerged as the most promising blood-based
biomarkers of Alzheimer's disease. Here, we performed a head-to-head comparison of p-tau181…

Importance Tau positron emission tomography (PET) tracers have proven useful for the
differential diagnosis of dementia, but their utility for predicting cognitive change is unclear. …

The authors discuss the cholinergic hypothesis of geriatric memory dysfunction, which
proposes the following:(1) Significant, functional disturbances in cholinergic activity occur in the …

The advent of tau-targeted positron emission tomography tracers such as flortaucipir ( 18 F-AV-1451,
also known as 18 F-T807) have made it possible to investigate the sequence of …